The Gates to Social Media are Opening for the Pharmaceutical Industry, but with Access Comes Responsibility

socialPills-1024x681Since social media was widely adopted more than five years ago, the pharmaceutical industry has tiptoed around the edges of the platform, concerned that diving in would obligate companies and brands to keep tabs on and manage all consumer-generated content. If the content is incorrect, patient outcomes and adherence could suffer; but in the absence of FDA guidance, and with limited resources, what can our industry do?

Until recently, there has been little feedback from the FDA regarding our perceived responsibility as an industry. However, the draft guidance published in January 2014 titled “Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics” appears to address pharma’s expanding role in engaging its audiences with promotional online activities, including what it can do with content after it’s been approved and published.

Read the full story on pharmaphorum’s website.

Zoe Dunn
Zoe Dunn, President and CEO of Hale Advisors, is a digital marketing and communications specialist with over twenty years of experience in the field. She has extensive experience in both the agency and commercial marketing side of the pharmaceutical, medical devices, and biotech industries.

Comments are closed.